apatinib
Showing 1 - 25 of 208
Digestive System Cancers Trial in Beijing (KN046, Regorafenib, Apatinib)
Recruiting
- Digestive System Cancers
- KN046
- +2 more
-
Beijing, ChinaPeking University Cancer Hospital
Oct 25, 2023
Nasopharyngeal Carcinoma Trial in Guangzhou (Camrelizumab, Gemcitabine, Cisplatin)
Recruiting
- Nasopharyngeal Carcinoma
- Camrelizumab
- +3 more
-
Guangzhou, Guangdong, ChinaDepartment of Nasopharyngeal Carcinoma, Sun Yat-sen University C
May 3, 2023
Gastric Cancer Trial in Tianjin (AK104, Apatinib, Paclitaxel)
Recruiting
- Gastric Cancer
- AK104
- +3 more
-
Tianjin, ChinaTianjin Medical University Cancer Institute and Hospital
May 7, 2023
Gastric Cancer Trial in Beijing (Apatinib, Oxaliplatin, S1)
Recruiting
- Gastric Cancer
- Apatinib
- +2 more
-
Beijing, Beijing, ChinaBeijing Cancer Hospital / Peking University Cancer Hospital
Jan 30, 2023
Breast Cancer Metastatic Cancer Trial in Shanghai (Apatinib, Dalpiciclib, Fulvestrant/AI)
Recruiting
- Breast Cancer Metastatic Cancer
- Apatinib
- +2 more
-
Shanghai, Shanghai, ChinaBreast cancer institute of Fudan University Cancer Hospital
Feb 26, 2023
Immunotherapy Gastrict Cancer Trial (Tislelizumab, apatinib, oxaliplatin)
Not yet recruiting
- Immunotherapy Gastrict Cancer
- Tislelizumab
- +3 more
- (no location specified)
Jan 17, 2023
Hepatocellular Carcinoma Trial in Nanjing (Camrelizumab, TACE, Apatinib)
Recruiting
- Hepatocellular Carcinoma
- Camrelizumab
- +2 more
-
Nanjing, Jiangsu, ChinaZhongda Hospital
Sep 8, 2022
Cancer Trial in Santa Monica (Apatinib, Nivolumab)
Active, not recruiting
- Cancer
- Apatinib
- Nivolumab
-
Santa Monica, CaliforniaSarcoma Oncology Research Center
May 19, 2022
Triple Negative Breast Cancer Trial in Chengdu (Camrelizumab, Apatinib, Nab-paclitaxel)
Not yet recruiting
- Triple Negative Breast Cancer
- Camrelizumab
- +4 more
-
Chengdu, Sichuan, ChinaWest China Hospital, Sichuan University
Jul 6, 2022
Thyroid Cancer Trial in Peking (Apatinib)
Completed
- Thyroid Cancer
- Apatinib
-
Peking, ChinaPeking Union Medical College Hospital
Jan 18, 2022
Gastric Cancer Trial in Shanghai (Apatinib)
Completed
- Gastric Cancer
- Apatinib
-
Shanghai, Shanghai, ChinaShanghai 6th People's Hospital
Feb 24, 2022
Hepatocellular Carcinoma Trial in Guangzhou (FOLFOX-HAIC, Camrelizumab, Apatinib)
Recruiting
- Hepatocellular Carcinoma
- FOLFOX-HAIC
- +2 more
-
Guangzhou, Guangdong, ChinaCancer Center Sun Yat-sen University
Jan 19, 2022
Esophageal Tumors Trial (Apatinib, The chemotherapeutic drug chosen by the investigator.)
Withdrawn
- Esophageal Neoplasms
- Apatinib
- The chemotherapeutic drug chosen by the investigator.
- (no location specified)
Apr 11, 2022
Gastric Cancer Trial in Xining, Yangquan (Apatinib)
Completed
- Gastric Cancer
- Apatinib
-
Xining, Qinghai, China
- +4 more
Mar 14, 2022
NSCLC Trial in Wuhan (Apatinib)
Enrolling by invitation
- NSCLC
- Apatinib
-
Wuhan, Hubei, ChinaHubei Cancer hospital
Feb 4, 2022
Advanced Primary Liver Cancer, Advanced Biliary Tract Carcinoma Trial in Zhengzhou, Nanjing (SHR-1210, Apatinib, FOLFOX4)
Active, not recruiting
- Advanced Primary Liver Cancer
- Advanced Biliary Tract Carcinoma
- SHR-1210
- +3 more
-
Zhengzhou, Henan, China
- +1 more
Apr 26, 2022
NSCLC Trial in Wuhan (Camrelizumab, Apatinib, Docetaxel injection)
Recruiting
- Non-Small Cell Lung Cancer
- Camrelizumab
- +4 more
-
Wuhan, Hubei, ChinaZhongnan Hospital of Wuhan University
Apr 29, 2022
Gastric Cancer Trial in Jinan (SHR1210, Apatinib, S1)
Recruiting
- Gastric Cancer
- SHR1210
- +3 more
-
Jinan, Shandong, ChinaQilu hospital of Shandong univertisy
Mar 30, 2022
Triple-Negative Breast Cancer Trial in Guangzhou (Apatinib)
Completed
- Triple-Negative Breast Cancer
- Apatinib
-
Guangzhou, Guangdong, China
- +1 more
Jan 29, 2022
Breast Cancer Trial in Shanghai (Apatinib, Paclitaxel, Cisplatin)
Recruiting
- Breast Cancer
- Apatinib
- +3 more
-
Shanghai, Shanghai, ChinaRenji Hospital, School of Medicine, Shanghai Jiao Tong Universit
Dec 18, 2021
Hepatocellular Carcinoma Trial in Guangzhou (Apatinib, Camrelizumab, NK cell)
Recruiting
- Hepatocellular Carcinoma
- Apatinib
- +2 more
-
Guangzhou, Guangdong, ChinaNanfang Hospital of Southern Medical University
Dec 26, 2021
Gastric Cancer, GastroEsophageal Cancer Trial in China (SHR-1210, Capecitabine, Oxaliplatin)
Completed
- Gastric Cancer
- GastroEsophageal Cancer
- SHR-1210
- +3 more
-
Hefei, Anhui, China
- +9 more
Jun 30, 2022
Intrahepatic Cholangiocarcinoma Trial in Guangzhou (Camrelizumab, Apatinib)
Recruiting
- Intrahepatic Cholangiocarcinoma
- Camrelizumab
- Apatinib
-
Guangzhou, Guangdong, ChinaLi Xu
Dec 8, 2021